This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.62% per year. These returns cover a period from January 1, 1988 through June 2, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
pharmaceuticals: Archive
Gene-Editing Stocks Gain on LLY-VERV Deal Announcement
by Ekta Bagri
LLY's move to buy Verve ignites investor interest across gene-editing stocks like CRSP, NTLA and BEAM in a booming M&A year.
LLYPositive Net Change BEAMPositive Net Change NTLANegative Net Change CRSPPositive Net Change VERVNegative Net Change
biotechnology biotechs gene-editing medical pharmaceuticals
Slowing Gardasil Sales Hurt MRK's Top Line: Is Recovery in the Cards?
by Zacks Equity Research
Merck's Gardasil sales decline due to weak demand trends in China, with new launches expected to offset the downside.
SNYPositive Net Change AZNPositive Net Change PFEPositive Net Change MRKPositive Net Change
pharmaceuticals
Verve Therapeutics Stock Soars 76% on $1.3B Buyout Offer From Lilly
by Zacks Equity Research
VERV jumps on Eli Lilly's buyout offer, adding next-gen gene-editing therapies to the pharma giant's pipeline.
SNYPositive Net Change BMYNegative Net Change LLYPositive Net Change VERVNegative Net Change
biotechs gene-editing gene-therapy medical pharmaceuticals
Incyte Stock Rises on QIAGEN Deal to Advance Blood Cancer Diagnostics
by Zacks Equity Research
INCY jumps 5.1% on a global QIAGEN deal to develop a companion diagnostic for its mutCALR-targeting cancer therapy.
BAYRYNegative Net Change QGENPositive Net Change INCYNegative Net Change IMCRPositive Net Change
biotechnology biotechs medical oncology-screening pharmaceuticals
Teva Partners With Fosun to Develop TEV-56278 Immuno-Cancer Therapy
by Zacks Equity Research
TEVA teams up with Fosun to speed the development of TEV-56278, a novel anti-cancer immunotherapy targeting PD-1+ T cells.
TEVANo Net Change BAYRYNegative Net Change AGENNegative Net Change IMCRPositive Net Change
biotechnology biotechs immuno-therapy medical oncology-screening pharmaceuticals
AbbVie's Venclexta Misses Goal in Myelodysplastic Syndromes Study
by Zacks Equity Research
Venclexta fails to meet survival goals in ABBV's phase III MDS study, marking another clinical setback for the cancer drug.
RHHBYNegative Net Change ABBVPositive Net Change AGENNegative Net Change IMCRPositive Net Change
biotechs medical pharmaceuticals
Company News for Jun 17, 2025
by Zacks Equity Research
Companies in The News Are: RNW, NOC, SRPT, AMD.
NOCPositive Net Change AMDNegative Net Change SRPTNegative Net Change RNWPositive Net Change
pharmaceuticals semiconductor
5 Low Price-to-Book Value Stocks That You Can Buy in June
by Kinjel Shah
The P/B ratio helps to identify low-priced stocks with high growth prospects. USNA, CVS, PFE, STNE and PSFE are some such stocks.
PFEPositive Net Change CVSPositive Net Change USNANegative Net Change STNEPositive Net Change PSFEPositive Net Change
business-services computers medical pharmaceuticals
4 Stocks With Solid Net Profit Margins to Boost Portfolio Returns
by Anirudha Bhagat
Here we present four stocks, GLDD, TILE, CPRX and STRL, with solid net profit margins that can contribute to making a strong portfolio.
STRLNegative Net Change GLDDNegative Net Change CPRXNegative Net Change TILENegative Net Change
construction industrial-products medical medical-devices pharmaceuticals transportation
Bull of the Day: Veeva Systems (VEEV)
by Benjamin Rains
The AI-boosted medical software stock that's tripled Tech over the last 10 years is on the verge of breaking above a key technical range while trading 15% below its highs.
VEEVPositive Net Change
artificial-intelligence medical pharmaceuticals tech-stocks
ADMA Looks to Expand Asceniv's Label: Will This Boost Sales?
by Zacks Equity Research
ADMA surges on soaring Asceniv demand and eyes pediatric label expansion to widen its immunodeficiency treatment reach.
GRFSPositive Net Change ADMAPositive Net Change TAKPositive Net Change
biotechnology biotechs medical pharmaceuticals
Novo Nordisk Stock Rises 6% in a Week: What Should Investors Do?
by Ahan Chakraborty
NVO jumps nearly 6% in a week on amycretin pipeline boost and hedge fund interest, but competition looms large.
NVOPositive Net Change LLYPositive Net Change AMGNPositive Net Change VKTXNegative Net Change
biotechnology biotechs medical pharmaceuticals
RHHBY to Advance Parkinson's Disease Drug to Late-Stage Development
by Zacks Equity Research
Roche is set to advance prasinezumab into phase III for early Parkinson's, eyeing potential first-in-class disease-modifying therapy.
NVSPositive Net Change RHHBYNegative Net Change BAYRYNegative Net Change PRTANegative Net Change
biotechnology biotechs medical pharmaceuticals
5 Large Drug Stocks That Are Poised to Ride on Sector Recovery
by Kinjel Shah
In the Large-Cap Pharmaceuticals industry, AbbVie, Novartis, Pfizer, Sanofi and Bayer are worth retaining amid macro pressure and rising innovation.
ABBVPositive Net Change SNYPositive Net Change NVSPositive Net Change PFEPositive Net Change BAYRYNegative Net Change
pharmaceuticals
Can J&J's Innovative Medicines Unit Sustain Growth Amid Stelara LOE?
by Kinjel Shah
JNJ's Innovative Medicines unit shows a growth trend, defying Stelara LOE and the negative impact of the Part D redesign.
JNJPositive Net Change PFEPositive Net Change AMGNPositive Net Change ABBVPositive Net Change
pharmaceuticals
SRPT Plummets on Second Patient Death After DMD Gene Therapy Infusion
by Zacks Equity Research
Sarepta's shares sink as second Elevidys-linked death triggers safety concerns, dosing halts and trial pauses.
RHHBYNegative Net Change SRPTNegative Net Change AGENNegative Net Change IMCRPositive Net Change
biotechs gene-editing gene-therapy medical pharmaceuticals
The Zacks Analyst Blog Highlights Eli Lilly, Home Depot, SAP and Natural Resource Partners
by Zacks Equity Research
Eli Lilly, Home Depot, SAP and NRP highlight key themes in pharma, retail, cloud growth???and energy sector challenges.
LLYPositive Net Change HDNegative Net Change SAPPositive Net Change NRPPositive Net Change
computers pharmaceuticals retail tech-stocks
Top Analyst Reports for Eli Lilly, Home Depot & SAP
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Eli Lilly and Company, The Home Depot and SAP SE.
LLYPositive Net Change DHRNegative Net Change HDNegative Net Change SAPPositive Net Change ORCLPositive Net Change NRPPositive Net Change PYPLPositive Net Change
pharmaceuticals tech-stocks
Lilly Moves Past 50-Day Average: Should You Buy the Stock Now?
by Kinjel Shah
LLY breaks above its 50-day average as Mounjaro and Zepbound drive revenues. Is this a new entry point for investors?
NVOPositive Net Change LLYPositive Net Change AMGNPositive Net Change VKTXNegative Net Change
pharmaceuticals
BMY Focuses on Label Expansion of Drugs: Will This Revive Growth?
by Ekta Bagri
BMY's banks on label expansion of drugs like Sotyktu and Opdivo to boost sales in the wake of generic competition for legacy drugs.
BMYNegative Net Change MRKPositive Net Change AMGNPositive Net Change
biotechnology biotechs medical pharmaceuticals
NVO Stock up on Plans to Advance Obesity Candidate Amycretin
by Zacks Equity Research
Novo Nordisk stock climbs following the announcement of its plans to advance amycretin, a dual GLP-1/amylin agonist for obesity, to phase III development.
NVSPositive Net Change NVOPositive Net Change LLYPositive Net Change BAYRYNegative Net Change
biotechnology biotechs medical pharmaceuticals
Company News for Jun 13, 2025
by Zacks Equity Research
Companies In The News Are: ORCL, GOOGL, BA, NVO.
BANegative Net Change NVOPositive Net Change ORCLPositive Net Change GOOGLNegative Net Change
aerospace internet pharmaceuticals tech-stocks
PFE's New & Acquired Drugs Hold Key to Revenue Growth Amid Headwinds
by Kinjel Shah
PFE's new drug launches and Seagen acquisition are driving revenue gains despite COVID declines and market headwinds.
AZNPositive Net Change BMYNegative Net Change PFEPositive Net Change MRKPositive Net Change
pharmaceuticals
BMY Reports Positive Data on Sotyktu From Arthritis Study
by Zacks Equity Research
Bristol Myers' Sotyktu hits key goals in late-stage PsA trial, fueling hopes for expansion amid recent pipeline setbacks.
NVSPositive Net Change BMYNegative Net Change BAYRYNegative Net Change BNTXNegative Net Change
biotechnology biotechs medical pharmaceuticals
Novavax's COVID-Flu Combo Shot Shows Strong Immune Response
by Zacks Equity Research
NVAX's COVID-flu combo shot sparks strong immunity in seniors, fueling plans for further late-stage trials.
SNYPositive Net Change PFEPositive Net Change MRNAPositive Net Change NVAXNegative Net Change
biotechs medical messenger-rna pharmaceuticals vaccines